OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.30

+4.4%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$58.80M
EPS-4.4000
P/E Ratio-0.98
Earnings Date08/11/2026

okur

Net Interest Income

Last Annual Value

3.44M

3-Year CAGR

138%

5-Year CAGR

%

10-Year CAGR

%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Net Interest Income

OKUR · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.44M
28.5%N/AN/A 
-4.12M
N/AN/AN/A
4.44M
-22.5%173.6%N/A
2.16M
20.3%75.0%N/A
-745.67K
N/AN/AN/A
3.40M
N/AN/AN/A
3.88M
7.7%82.8%N/A
4.56M
-17.1%N/A43.8%
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.3, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.3